EntryPoint Capital’s Takeda Pharmaceutical TAK Stock Holding History

EntryPoint Capital’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,971	Closed	-$185K	–	941
2024 Q4	$185K	Sell	13,971 -1,833	-12%	-$25.2K	0.08%	605
2024 Q3	$225K	Buy	+15,804	New	+$224K	0.13%	393

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

EntryPoint Capital's TAK Position: Q1 2025 in Review

EntryPoint Capital sold out of Takeda Pharmaceutical (TAK) in Q1 2025, closing a stake of 13,971 shares — an estimated $185K sold.

EntryPoint Capital first reported a position in TAK in Q3 2024 and held it in 2 quarters. The position peaked at $225K in Q3 2024. 307 funds tracked by Wall St. Rank hold TAK as of Q1 2025.

EntryPoint Capital reported no remaining Takeda Pharmaceutical position as of Q1 2025 after selling out during the quarter.
EntryPoint Capital sold 13,971 Takeda Pharmaceutical shares in Q1 2025, an estimated $185K.
EntryPoint Capital first reported a position in Takeda Pharmaceutical in Q3 2024 and held it in 2 quarters.
EntryPoint Capital's Takeda Pharmaceutical position peaked at $225K in Q3 2024.
307 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2025.

Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.